An analysis of circulating markers of early progression in patients treated with Fulvestrant and palbociclib/placebo in the PALOMA 3 trial showed that circulating tumor fraction, TP53 mutation, and FGFR1 gain were each independently associated with risk of early relapse for both Fulvestrant alone and Fulvestrant plus palbociclib subgroups [19]. This evidence concerns the gene TP53 and neoplasm.